echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Heavy: CDE has focused on clinical trials of improved new drugs for children's chemicals

    Heavy: CDE has focused on clinical trials of improved new drugs for children's chemicals

    • Last Update: 2021-07-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 13, 2021, the official website of the Center for Drug Evaluation of the National Medical Products Administration issued the " Technical Guidelines for Clinical Trials of Modified New Drugs for Children's Chemicals (Draft for Comment)", and the deadline is May 12, 2021
    .
    This guideline is to encourage the development of new and improved chemicals for children based on the characteristics of children's growth and development and the needs of pediatric clinical practice based on the clinical needs of pediatrics in China


    .


    1.
    Regulatory definitions related to improved new drugs

    Formulation improvement is one of the important ways for new drug research and development.
    After the implementation of the "Administrative Measures for Drug Registration" that China implemented on July 1, 2020, the registration of chemical drugs is classified into 5 categories, namely, innovative drugs that have not been marketed at home or abroad, and domestically unlisted innovative drugs.
    Improved new drugs that have not been listed abroad, drugs that domestic applicants imitate overseas but not domestically marketed original research drugs, domestic applicants imitate drugs that have been listed domestically, and drugs that have been listed overseas apply for listing in China; according to the "Chemical Drugs" "Registration Classification and Application Information Requirements", the improved new drugs that have not been marketed at home or abroad belong to the second category of new drugs (subdivided into four categories 2.
    1, 2.
    2, 2.
    3, and 2.
    4), which means that their structure is based on the known active ingredients.
    Drugs with obvious clinical advantages through optimization of dosage form, prescription process, route of administration, indications, etc.
    ; improved drugs marketed overseas belong to category 5.
    1, regardless of category 2 or 5.
    1, improved drugs are required to have obvious clinical Advantage is the key condition.
    The definition is excerpted as follows:

    ♦ Class 2.
    1, containing optical isomers of known active ingredients prepared by resolution or synthesis, or forming esters with known active ingredients, or forming salts with known active ingredients (including hydrogen bonds or coordination Bond salt), or change the acid radical, base or metal element of the active ingredient of known salt, or form other non-covalent bond derivatives (such as complex, chelate or clathrate), and have obvious clinical Advantage of medicine
    .

    ♦ Class 2.
    2, new dosage form (including new drug delivery system), new prescription technology, new route of administration with known active ingredients, and drugs with obvious clinical advantages
    .

    ♦ Class 2.
    3, a new compound preparation with known active ingredients, and has obvious clinical advantages
    .

    ♦ Category 2.
    4, drugs with new indications containing known active ingredients
    .

    ♦ In category 5.
    1, original research drugs and modified drugs that are listed overseas apply for listing in China
    .
    Improved drugs should have obvious clinical advantages


    .


           2.
    Common improvements and cases of improved new drugs for children

           To provide children with safe, effective, controllable quality and suitable for children of different ages is the goal of children's drug development
    .
    Optimizing improved new drugs with obvious clinical advantages for children on the basis of known active ingredient drugs is a common choice for expanding children's applications.


    This guiding principle focuses on the current common development/expansion of children's applications and common situations of improving children's preparations


           1.


           2.


           references

           [1] http://       About the author: Drip Sinan, male, senior engineer in biomedicine, based on the quality management of the biomedical industry, focusing on the biomedical industry


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.